患有癌症的狗的生活质量（QOL）是评估癌症治疗方案的一个关键考虑因素。尽管人们对改善肿瘤患者管理的饮食策略很感兴趣，但很少有临床研究表明饮食对狗化疗不良反应的影响。这项研究是一项随机、对照、双盲、多中心临床试验，旨在研究补充 omega-3 脂肪酸的高蛋白、高纤维饮食，用于治疗接受标准化疗的癌症犬。客户拥有的新诊断患有 2 级或更高级别肥大细胞肿瘤（或不可切除/不完全切除的肿瘤）或多中心淋巴瘤的狗被随机分配接受测试饮食 (n = 24) 或对照饮食 (n = 21)，为期 8 周。主要结果是生活质量评估、粪便评分以及 C 反应蛋白和单核细胞趋化蛋白 1 的血液浓度。在 12 个 QOL 参数中，与对照组相比，测试组中有 10 个参数从基线到第 8 周显着改善。然而，两组之间的差异仅在“疾病体征频率”方面具有统计学意义（P = .009）。两组之间任何不良事件的发生率没有显着差异，包括胃肠道不良事件或实验室参数或粪便评分的临床显着差异。由于没有观察到测试饮食的负面影响，加上与饮食相关的生活质量改善程度，表明有必要进行更大规模的试验。© 2023 John Wiley

Quality of life (QOL) in dogs with cancer is a key consideration in the assessment of cancer treatment options. Despite interest in dietary strategies to improve management of oncology patients, there have been very few clinical studies showing the impact of diet on adverse effects of chemotherapy in dogs. This study was a randomised, controlled, double-blinded, multicenter clinical trial to investigate a high-protein, increased-fibre diet supplemented with omega-3 fatty acids, for dogs with cancer undergoing standard-of-care chemotherapy. Client-owned dogs with newly diagnosed grade 2 or higher mast cell tumours (or non-resectable/incompletely resected tumours) or multicentric lymphoma were randomised to receive the test diet (n = 24) or control diet (n = 21) for 8 weeks. Primary outcomes were QOL assessments, faecal scores, and blood concentrations of C-reactive protein and monocyte chemoattractant protein-1. Of 12 QOL parameters, 10 significantly improved from baseline to Week 8 in the test group compared with one in the control group. However, differences between the two groups were only statistically significant for 'frequency of signs of illness' (P = .009). There were no significant differences in the incidence of any adverse events, including gastrointestinal adverse events or clinically significant differences in laboratory parameters or faecal scores between the two groups. The absence of an observed negative impact of the test diet, combined with the magnitude of QOL improvements associated with the diet, suggest that a larger trial is warranted.© 2023 John Wiley & Sons Ltd.